ENEA Tech Video

BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.

Coming soon

Events

See what BetaGlue will attend
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®
Website Launch

BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®

Milan, April 30, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue® Secures €10m EIC Accelerator Award
EU Logo

BetaGlue® Secures €10m EIC Accelerator Award

Milan, March 4, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products in the field of loco-regional radiotherapy to treat solid…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer
Salvatore Calabrese CFO, BetaGlue

BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer

Milan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco-…

Read more
1200 800 Betaglue® Therapeutics